Recent billion-dollar successes in the French biotech ecosystem, such as Abivax and Medincel, are largely credited to their management teams. These leaders often have significant experience working in the US and other countries. This global perspective enables them to develop assets for a worldwide market, navigate different regulatory environments, and attract international funding, breaking the mold of previously localized French biotechs.

Historically, the French biotech scene was held back by a lack of large domestic investment funds. This has changed significantly, with local VCs now raising large funds capable of leading nine-figure rounds. This growing financial muscle allows French biotechs to scale effectively within their own ecosystem.

The biotech landscape in Southeast Asia has strong scientific talent but lacks a mature 'translation ecosystem' (VCs, experienced operators). Founders must take on the dual role of building their company and simultaneously cultivating the surrounding infrastructure, including talent, partnerships, and public trust.

Beyond funding and regulatory hurdles, Europe's restrictive drug pricing environment is a fundamental threat. It discourages pharmaceutical companies, including Europe's own, from investing in the region as they prioritize the more profitable US market. This ultimately undermines the entire local R&D ecosystem.

Europe's decentralized biotech ecosystem offers a major operational advantage over hubs like Boston. Lower competition for talent, lab space, and clinical trial sites allows startups to operate at 50% of the cost, coupled with pre-money valuations that are often 40% lower, creating significant capital efficiency.

The Institute of Organic Chemistry and Biochemistry (IOCB) in Prague demonstrates how academic centers can build entire ecosystems. By using royalty income from major drug discoveries, it funded a dedicated technology transfer company (IOCB Tech) and even a US branch, creating a self-sustaining innovation engine.

Unlike their US counterparts, European biotechs have less access to large venture funds. This forces a culture of extreme capital efficiency and discipline. This need to be "cleverer, smarter with less people and less money" is a defining feature and potential advantage of the European ecosystem.

The coalition's core mission is to prevent the exodus of successful biotechs to the US. By building a stronger capital market, they aim to keep champion companies like Argenx headquartered and operating in Europe, ensuring economic value, market capitalization, and tax revenues benefit the region, not the US.

Thriving life sciences ecosystems in Ireland, the UK, and Massachusetts did not grow by accident. Their success is the result of deliberate, long-term government strategies, including tax incentives, shared R&D infrastructure like the UK's 'Catapult' network, and fostering deep connections between technology, hospitals, and capital.